[On Demand]

Traditional chemotherapies save lives but are limited by side effects. Reglagene is at the forefront of innovation by developing orally administered Precision Chemotherapies that limit toxicities and work on difficult-to-treat cancers. Precision Chemotherapy is a category of Precision Medicine, and we have found a safe way to selectively induce DNA damage in cancer cells, while leaving healthy cells alone. We aim to have our first Precision Chemotherapy entering the clinic in late 2022.


Reglagene is presenting as part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
RHI168 - Orally Administered Small Molecule for Rare Cancers
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chief Executive Officer
Reglagene Holding, Inc.